NCT00554970View on ClinicalTrials.gov

A Study of 2 Doses of MAP0010 in Adult Asthmatics

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

March 31, 2008

Conditions
Asthma
Interventions
DRUG

MAP0010 low dose

a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol

DRUG

MAP0010 high dose

a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol

DRUG

Budesonide inhalation suspension 0.25mg

a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol

DRUG

Budesonide inhalation suspension 0.5mg

a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol

Trial Locations (1)

90806

West Coast Clinical Trials Phase 2-4, LLC, Long Beach

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
collaborator

MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

INDUSTRY

lead

Allergan

INDUSTRY

NCT00554970 - A Study of 2 Doses of MAP0010 in Adult Asthmatics | Biotech Hunter | Biotech Hunter